Pfizer's Groton cuts slightly top earlier estimates; Warner Chilcott sees lower-than-expected 2013 earnings;

@FiercePharma: Corks pop at Sanofi as FDA nixes Novo's Lantus challenger. Article | Follow @FiercePharma

@EricPFierce: New Celgene drug for multiple myeloma expected to help fuel expansion of market to $7.2 billion. News | Follow @EricPFierce

@AlisonBFierce: A genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival more than a year. More | Follow @AlisonBFierce

> Pfizer ($PFE) shrank its Groton, CT, workforce more than expected during a company restructuring, with around 3,300 people now employed there compared with its target of 3,400; that's down from 4,500 two years ago. Report

> Warner Chilcott ($WCRX) put up a 2013 forecast that fell short of analyst estimates because of increases in R&D expenses related to late-stage products. Report

> California drugmaker Titan Medical Enterprises was ordered to shut down after a U.S. judge ruled that the company didn't follow FDA manufacturing rules and sold unapproved drugs. Report

> Takeda and partner Sucampo sued Anchen and Par Pharmaceuticals for patent infringement after the generics makers asked FDA to approve copies of the bowel treatment Amitiza. Report

> Celgene's ($CELG) multiple myeloma drug Revlimid won approval from Japanese regulators for patients who've failed on at least one prior therapy. Report

> Pharmaceutical exports to Iran dropped by half last year, new data show, suggesting that economic sanctions are affecting "humanitarian" trade as well as other goods. Report

> Roman Catholic bishops rejected the Obama administration's attempt at a compromise on health-plan coverage of contraceptives. Report

Medical Device News

 @FierceMedDev: Israeli team advances genetic device to perform DNA diagnosis. Report | Follow @FierceMedDev

 @MarkHFierce: Indiana offers a way to work around the device tax, rather than focusing on repealing it. More | Follow @MarkHFierce

 @DamianFierce: Pfizer's ongoing R&D slash and burn could be good news for CROs. Story | Follow @DamianFierce

> Japan's regulators push for quicker device approval process. News

> Indiana mulls industry tax break to counter federal device tax. Report

Biotech News

 @FierceBiotech: Sanofi move to acquire more shares of Regeneron triggers market buzz. Report | Follow @FierceBiotech

@JohnCFierce: Tresiba news underscores how high the FDA sets the bar on diabetes. Hard for biotechs to play in a field like this. News | Follow @JohnCFierce

@RyanMFierce: 'Mercenary' coders crowd-sourced for immunology research software. Report | Follow @RyanMFierce

> Bayer hands off FDA app as pulmonary hypertension drug race heats up. Story

> Spurning panel endorsement, FDA rejects Novo's long-acting insulin Tresiba. Article

CRO News

> GSK ups the ante for trial transparency. Story

> Struggling Cardiome recruits Quintiles to handle heart drug. More

> Struggling Cardiome recruits Quintiles to handle heart drug. News

> QPS snags Florida trial site amid buying spree. Report

> Pfizer's Singapore slash and burn could be good news for CROs. Article

Biotech IT News

> Trials software outfit BioClinica reports annual results (for the last time?) Item

> Sanofi backs mobile service for cancer patients on chemo. News

> 'Mercenary' coders crowd-sourced for immunology research software. Report

> Biotech, pharma warming up to Facebook. Article

> Eli Lilly's virtual unit taps Oracle software for clinical trials. Story

And Finally... Want to be more productive? Stop working so hard. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.